InterCure (NASDAQ:INCR) Trading 9.4% Higher – Still a Buy?

Shares of InterCure Ltd. (NASDAQ:INCR) traded up 9.4% during trading on Monday . The stock traded as high as $0.9556 and last traded at $0.9560. 73,559 shares changed hands during trading, an increase of 24% from the average session volume of 59,395 shares. The stock had previously closed at $0.8740.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of InterCure in a report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

InterCure Trading Down 2.2%

The stock has a market cap of $51.34 million, a price-to-earnings ratio of 31.30 and a beta of 1.38. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.97 and a current ratio of 1.48. The company’s 50 day simple moving average is $0.87 and its two-hundred day simple moving average is $0.94.

InterCure (NASDAQ:INCR) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.10) EPS for the quarter. The firm had revenue of $23.15 million for the quarter.

About InterCure

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.